Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies

Brigatinib and brigatinib-analog are potent and selective ALK inhibitors with the similar structure. A simple and sensitive high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of brigatinib and brigatinib-analog in rat plasma and brai...

Full description

Bibliographic Details
Published in:	International Journal of Analytical Chemistry
Main Authors:	Bo Li, Min Lu, Lei Jin, Maoen Zheng, Peilu Sun, Shanshan Lei, Shan Xiong, Suhong Chen
Format:	Article
Language:	English
Published:	Wiley 2019-01-01
Online Access:	http://dx.doi.org/10.1155/2019/9028309

Similar Items

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib
by: Yuki Sato, et al.
Published: (2024-08-01)

LC-MS/MS Method for Simultaneous Quantification of Dexmedetomidine, Dezocine, and Midazolam in Rat Plasma and Its Application to Their Pharmacokinetic Study
by: Wenjuan Cui, et al.
Published: (2018-01-01)

Safety of brigatinib following alectinib-induced-pneumonitis: Case report
by: Blerina Resuli, et al.
Published: (2025-01-01)

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach
by: Michael J. Hanley, et al.
Published: (2024-04-01)

Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib
by: Jia YU, et al.
Published: (2025-06-01)

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells
by: Qi Yang, et al.
Published: (2025-02-01)

Pleuritis Induced by Brigatinib During the Treatment of Non‐Small Cell Lung Cancer
by: Shohei Yano, et al.
Published: (2026-05-01)

Simultaneous quantification of lidocaine and prilocaine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study
by: Siva Sankara Rao Yadlapalli, et al.
Published: (2019-11-01)

Development and validation of an LC–MS/MS method for the simultaneous quantification of milbemycin oxime and praziquantel in plasma: application to a pharmacokinetic study in cats
by: Shiting Xie, et al.
Published: (2023-10-01)

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
by: Kyuhwan Kim, et al.
Published: (2025-02-01)

Soluplus–TPGS Mixed Micelles as a Delivery System for Brigatinib: Characterization and In Vitro Evaluation
by: Raisuddin Ali, et al.
Published: (2024-09-01)

Pharmacokinetics and brain distribution of the therapeutic peptide liraglutide by a novel LC–MS/MS analysis
by: Hyeon Seok Oh, et al.
Published: (2023-03-01)

Quantification of tolvaptan in rabbit plasma by LC–MS/MS: Application to a pharmacokinetic study
by: Kumar S. Moola, et al.
Published: (2015-12-01)

Quantification of Acipimox in Plasma and Tissues by LC–MS/MS: Application to Pharmacokinetic Comparison between Normoxia and Hypoxia
by: Xin Shen, et al.
Published: (2022-09-01)

High efficacy of brigatinib for brain metastases in ALK fusion gene‐positive non‐small cell lung cancer: A case series
by: Kei Morikawa, et al.
Published: (2024-02-01)

Largazole Pharmacokinetics in Rats by LC-MS/MS
by: Mingming Yu, et al.
Published: (2014-03-01)

LC–MS/MS quantification of 20(S)-protopanaxadiol in complex biological matrices for bioanalytical method validation and pharmacokinetic analysis
by: Pengfei Li, et al.
Published: (2025-05-01)

Unilateral cystic and bullous lung changes in a patient treated with brigatinib: a case report
by: Anuradha Nalika Godallage, et al.
Published: (2025-08-01)

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
by: Daphnée Demers, et al.
Published: (2025-05-01)

Brigatinib-repurposed chemo-photodynamic therapy nanoplatform via effective apoptosis against colorectal cancer
by: Miao Su, et al.
Published: (2023-02-01)

Methylation Enables Sensitive LC-MS/MS Quantification of Ciclopirox in a Mouse Pharmacokinetics Study
by: Roshan Katekar, et al.
Published: (2025-09-01)

Quantification of desloratadine in human plasma by LC-ESI-MS/MS and application to a pharmacokinetic study
by: Venkata Suresh Ponnuru, et al.
Published: (2012-06-01)

Quantification of oteseconazole in rat plasma using LC-MS/MS and its application to pharmacokinetic study
by: Krishna Phani Chandra Susararla, et al.
Published: (2024-08-01)

LC/MS/MS in drug development: targeting the brain
by: Pengfei Song, et al.
Published: (2005-06-01)

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC
by: Neeraj Gupta, et al.
Published: (2022-05-01)

Multiplex LC–MS/MS assay for simultaneous quantification of artesunate and its active metabolite dihydroartemisinin with pyronaridine, proguanil, cycloguanil, and clindamycin in pharmacokinetic studies
by: Christoph Pfaffendorf, et al.
Published: (2025-05-01)

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
by: Yang Zhang, et al.
Published: (2025-01-01)

Early Onset Pulmonary Events and Management Strategies during the Treatment of  ALK Positive NSCLC Patients with Brigatinib
by: Mingyi YANG, et al.
Published: (2023-04-01)

Protocol for the simultaneous quantification of oxidative purine lesions in DNA using LC-MS/MS analysis
by: Chryssostomos Chatgilialoglu, et al.
Published: (2024-09-01)

Development and validation of LC-MS/MS method for tomivosertib quantification in plasma: insights into pharmacokinetics and metabolic stability
by: Mamata Panthi, et al.
Published: (2025-07-01)

Simultaneous determination of venetoclax and obinutuzumab by LC-MS/MS and its application to pharmacokinetic drug interaction studies
by: Modachakanahally K Pavithra, et al.
Published: (2026-06-01)

Plasmalogen Profiling in Porcine Brain Tissues by LC-MS/MS
by: Yue Wu, et al.
Published: (2023-08-01)

Protoporphyrin IX plasma and blood pharmacokinetics and brain tumor distribution determined by a validated LC–MS/MS method
by: William Knight, et al.
Published: (2025-07-01)

A Selective and Accurate LC-MS/MS Method for Simultaneous Quantification of Valsartan and Hydrochlorothiazide in Human Plasma
by: Anzarul Haque, et al.
Published: (2023-02-01)

HPLC–PDA and LC–MS/MS Analysis for the Simultaneous Quantification of the 14 Marker Components in Sojadodamgangki-Tang
by: Chang-Seob Seo, et al.
Published: (2020-04-01)

A Case of Adjuvant Brigatinib in a Patient with ALK-rearranged R0 Resected Oligometastatic Lung Cancer
by: Oktay Ünsal, et al.
Published: (2025-10-01)

Simultaneous determination of acetaminophen and oxycodone in human plasma by LC–MS/MS and its application to a pharmacokinetic study
by: Wei Lu, et al.
Published: (2018-06-01)

Determination of Scopolamine Distribution in Plasma and Brain by LC-MS/MS in Rats
by: Juan Chen, et al.
Published: (2022-01-01)

LC–MS/MS-based in vitro and in vivo investigation of blood–brain barrier integrity by simultaneous quantitation of mannitol and sucrose
by: Behnam Noorani, et al.
Published: (2020-10-01)

Sensitive UPLC–MS/MS Method for Oxycodone Quantification in Serum and Brain Tissue Homogenates: Application to an Interaction Study in Rats
by: David Nakhla, et al.
Published: (2020-07-01)